Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia

Area of Science:

• Mycology
• Pediatric Oncology
• Infectious Diseases

Background:

• Mucormycosis is a rare but severe fungal infection in pediatric oncology patients.
• It is associated with high rates of morbidity and mortality, especially during intensive chemotherapy for acute lymphoblastic leukemia (ALL).

Purpose of the Study:

• To describe the clinical characteristics and outcomes of pediatric patients with acute lymphoblastic leukemia who developed mucormycosis during induction chemotherapy.
• To highlight the importance of early diagnosis and a multidisciplinary approach in managing this life-threatening infection.

Main Methods:

• Retrospective case series of five pediatric patients diagnosed with mucormycosis during induction chemotherapy for ALL.
• Chemotherapy regimens were modified to balance leukemia control with minimizing immunosuppression during antifungal treatment.

Main Results:

• All five patients survived their mucormycosis infection, including those with disseminated disease.
• Chemotherapy modification was successfully employed to manage both the leukemia and the fungal infection.
• Rapid diagnosis and a multidisciplinary team approach were crucial for successful outcomes.

Conclusions:

• Mucormycosis, despite its high fatality rate, can be effectively managed in pediatric oncology patients.
• A tailored, multidisciplinary strategy involving modified chemotherapy and prompt antifungal treatment can lead to survival, even in complex cases of disseminated disease during intensive cancer therapy.